Inhibiting 5‐lipoxygenase prevents skeletal muscle atrophy by targeting organogenesis signalling and insulin‐like growth factor‐1

BACKGROUND: Skeletal muscle atrophy can occur in response to numerous factors, such as ageing and certain medications, and produces a major socio‐economic burden. At present, there are no approved drugs for treating skeletal muscle atrophy. Arachidonate 5‐lipoxygenase (Alox5) is a drug target for a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyun‐Jun, Kim, Seon‐Wook, Lee, Sang‐Hoon, Jung, Da‐Woon, Williams, Darren R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745465/
https://www.ncbi.nlm.nih.gov/pubmed/36221153
http://dx.doi.org/10.1002/jcsm.13092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745465/
https://www.ncbi.nlm.nih.gov/pubmed/36221153
http://dx.doi.org/10.1002/jcsm.13092

Ejemplares similares